Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...
In the Spanish city of Murcia, an explosion occurred at the plant of the German company Rheinmetall, which manufactured ...
Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...
It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...
In imported Lay's chips, traces of six allergens were found at once, which the manufacturer did not inform about on the ...
Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.
One of the standout projects making waves in this space is Monsta Mash, a GameFi ecosystem that is drawing significant attention from large investors due to its incredibly low entry price of $0.00365.
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...
Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...
Shares of Akero Therapeutics ($AKRO) skyrocketed on Monday following game-changing results from its lead drug, efruxifermin, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback